Please assess the completion status of the following clinical trial:

Trial Title: Resection in Pancreatic Cancer With Minimal Metastatic Disease or Venous Infiltration Trial at Technische Universität München

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* suspicion of cancer of the pancreas and an intraoperative histologically proven diagnosis of pancreatic adenocarcinoma.~* intraoperative assessment of tumor as potentially locally resectable~* COHORT 1: Minimal metastatic disease~* COHORT 2: Venous infiltration~* ability to sign the informed consent.~* Karnofsky performance status \> 70.~* Life-expectancy of more than 3 months.~* able to attend follow-up.~* no previous or concurrent malignancy diagnoses, except non-melanoma skin cancer and in situ carcinoma of the cervix.~* no serious medical, psychological, familial, sociological or geographical conditions potentially hampering compliance with the study protocol and follow-up.~* patients older than 18 years.~* no pregnant or lactating women.~* preoperative evaluation by thin-sliced CT scans with:~* No evidence of substantial extra-pancreatic disease, i.e. no evidence of malignant ascites, extended liver metastasis (\>5 metastatic lesions), spread to other distant abdominal organs, peritoneal metastasis, spread to extra-abdominal organs.~* No evidence of extension of the tumor into the celiac axis or superior mesenteric artery (T4 disease).~* intraoperative findings with:~* tumor assessed as potentially locally resectable.~* no signs of peritoneal metastasis or tumor manifestations outside of the pancreas and the liver.~* frozen section: adenocarcinoma~Exclusion Criteria:~* extrapancreatic disease (except minimal metastatic disease of the liver, see above)~* concomitant venous infiltration and minimal metastatic disease~* extension of the tumor into the celiac axis or superior mesenteric artery~* life expectancy of less than 3 months~* previous or concurrent malignancy diagnosis, except non-melanoma skin cancer and in situ carcinoma of the cervix~* conditions potentially hampering compliance (also inclusion criteria)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): COHORT 1 (minimal metastatic disease):~* Arm 1 (intervention): resection of the primary tumor, followed by resection of the liver metastasis/metastases~* Arm 2 (control): exploration and/or gastroenterostomy and/or hepaticojejunostomy/choledochojejunostomy
- 2 (Type: ACTIVE_COMPARATOR): COHORT 2 (venous infiltration):~* Arm 1 (intervention): resection of the primary tumor with resection of the portal vein (and/or superior mesenteric vein/splenic vein (SMV/SV)~* Arm 2 (control): resection of the primary tumor with dissection of the portal vein (and/or superior mesenteric vein/splenic vein (SMV/SV) plus tumor masses adjacent to these veins; no venous resection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy